Ema launches review of Pflovid, Pfizer’s anti-Covid drug

Ema, avviata la revisione di Paxlovid, il farmaco anti Covid di Pfizer

Rome, 23 November – The European Medicines Agency announced last Friday, 19 November, the launch of a review for Paxlovid, the Pfizer pill against Covid. The EMA says it has begun reviewing the data currently available on the drug, which should represent a step forward on the home care front, and has begun reviewing it. “To support national authorities who could decide on its timely use, for example in emergencies, before the marketing authorization.”

The CHMP’s Committee for Medicinal Products for Human Use, the EMA says, will look at data from a study comparing the effects of Paxlovid compared with placebo in patients with mild to moderate Covid who are not being treated but are at risk of developing a serious illness. Preliminary results show that treatment reduced the risk of hospitalization or death compared with placebo when administered within 3 to 5 days of the onset of symptoms. The CHMP will also review data on the quality and safety of the drug.

“Although a more comprehensive rolling review is expected to begin before a possible marketing authorization application” determine the Community regulatory authority “This review will provide recommendations across the EU as soon as possible so that they can be used by national authorities wishing to make decisions based on evidence of timely use of the drug. “

Source link